UY27296A1 - Composición farmacéutica que contiene mosaprida y pancreatina - Google Patents

Composición farmacéutica que contiene mosaprida y pancreatina

Info

Publication number
UY27296A1
UY27296A1 UY27296A UY27296A UY27296A1 UY 27296 A1 UY27296 A1 UY 27296A1 UY 27296 A UY27296 A UY 27296A UY 27296 A UY27296 A UY 27296A UY 27296 A1 UY27296 A1 UY 27296A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical composition
pancreatin
composition containing
containing mosapride
mosapride
Prior art date
Application number
UY27296A
Other languages
English (en)
Inventor
Joaquina Faour
Juan Antonio Vergez
Marcelo A Ricci
Original Assignee
Osmotica Argentina S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osmotica Argentina S A filed Critical Osmotica Argentina S A
Publication of UY27296A1 publication Critical patent/UY27296A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición farmacéutica que contiene mosaprida, pancreatina y opcionalmente simeticona y es utilizada para el tratamiento, prevención o alivio de los síntomas de un desorden gastrointestinal. La composición farmacéutica es provista en una forma de dosificación oral para la administración a un sujeto.
UY27296A 2001-05-23 2002-05-20 Composición farmacéutica que contiene mosaprida y pancreatina UY27296A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/864,767 US6676933B2 (en) 2001-05-23 2001-05-23 Pharmaceutical composition containing mosapride and pancreatin

Publications (1)

Publication Number Publication Date
UY27296A1 true UY27296A1 (es) 2003-04-30

Family

ID=25344028

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27296A UY27296A1 (es) 2001-05-23 2002-05-20 Composición farmacéutica que contiene mosaprida y pancreatina

Country Status (3)

Country Link
US (1) US6676933B2 (es)
AR (1) AR034231A1 (es)
UY (1) UY27296A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03006251A (es) * 2001-01-12 2004-10-15 Innovation Ventures Llc Composicion a base de carbon vegetal activado y metodo para reducir sintomas de resaca asociados con el consumo de bebidas que contienen alcohol.
TW200418486A (en) * 2003-01-31 2004-10-01 Takeda Chemical Industries Ltd Solid preparation
PT1729797E (pt) * 2004-03-22 2008-12-17 Solvay Pharm Gmbh Composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina, contendo tensioactivos
CN1993131B (zh) * 2004-07-28 2010-10-13 大日本住友制药株式会社 薄膜包衣片
KR101038403B1 (ko) 2004-07-28 2011-06-01 다이닛본 스미토모 세이야꾸 가부시끼가이샤 복수의 층을 갖는 필름-코팅된 정제
US7153504B2 (en) * 2004-07-30 2006-12-26 Can Technologies, Inc. Stabilized pancreas product
EP1913138B1 (en) 2005-07-29 2016-08-24 Abbott Laboratories GmbH Processes for the manufacture of pancreatin powder with low virus content
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US20070077836A1 (en) * 2005-09-30 2007-04-05 General Electric Company Methods and apparatus for stabilizing exposed fabric edge
US8071089B2 (en) * 2005-11-01 2011-12-06 Bio-Cat, Inc. Composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrosis as well as people suffering from pancreatic lipase insufficiency
WO2007052837A1 (en) * 2005-11-04 2007-05-10 Ajinomoto Co., Inc. Gastrointestinal function promoter
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
CA2667890C (en) * 2006-10-31 2015-01-27 Surmodics Pharmaceuticals, Inc. Spheronized polymer particles
WO2008131259A1 (en) * 2007-04-19 2008-10-30 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
KR101143997B1 (ko) * 2010-03-04 2012-05-09 한미사이언스 주식회사 유산균 제제 및 5-ｈｔ4 수용체 효능제를 함유하는 경구 투여용 복합 제제 및 이의 제조방법
MX2010012479A (es) * 2010-11-16 2012-05-16 Posi Visionary Solutions Llp Composicion farmaceutica de administracion oral para el tratamiento del sindrome de intestino irritable, a base de un modificador de la motilidad intestinal, un agente que previene la retencion de gases y enzimas digestivas y proceso para su preparacion.
ITMI20120131A1 (it) * 2012-02-01 2013-08-02 Probiotical Spa Batteri probiotici microincapsulati multistrato, loro produzione ed uso
EP3162371A1 (en) * 2015-10-27 2017-05-03 Przemyslaw Taciak A composition comprising simethicone, gastric acid-neutralizing substances and gastric enzyme(s) (e.g. pancreatine) for use in the treatment of digestive disorders
EP3509428B1 (en) 2016-09-09 2021-06-16 International Agriculture Group, LLC Natural cocoa alternative
WO2018049242A1 (en) 2016-09-09 2018-03-15 International Agriculture Group, LLC Yogurt product from high starch fruits
MX2017001714A (es) * 2017-02-07 2018-08-06 Rhein Siegfried Sa De Cv Composicion de liberacion rapida de cinitaprida y simeticona y proceso para prepararla.
KR102648960B1 (ko) * 2017-09-29 2024-03-20 존슨 앤드 존슨 컨수머 인코포레이티드 고체 시메티콘 입자 및 이의 투여 형태
CN110721151B (zh) * 2019-11-29 2023-09-12 远大生命科学(武汉)有限公司 一种西甲硅油复方液体组合物及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2166730A1 (en) 1993-07-06 1995-01-19 Robert T. Sims H2 antagonist-gastrointestinal motility agent combinations

Also Published As

Publication number Publication date
US6676933B2 (en) 2004-01-13
AR034231A1 (es) 2004-02-04
US20030007962A1 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
UY27296A1 (es) Composición farmacéutica que contiene mosaprida y pancreatina
ES2552639T3 (es) Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos
AR038527A1 (es) Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo
AR005281A1 (es) Composicion farceutica oral , procedimientos para su manufactura y uso de esa composicion farmaceutica para la preparacion de medicamentos. .
CO5611096A2 (es) Forma de dosificacion farmaceutica para administracion mucosal
CO5640087A2 (es) Composiciones de farmacos anti-inflamatorios no esteroideos descongestionantes y anti-histaminicos
SE9600072D0 (sv) New oral formulation of two active ingredients II
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
ES2172654T3 (es) Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe.
HUP0301868A2 (hu) Gyógyászati készítmény, ami VIIa és XIII-as faktort tartalmaz
CR6326A (es) Formulaciones farmaceuticas de liberacion controlada
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
CY1106845T1 (el) Χρηση της φλουμαζενιλης για την παρασκευη ενος φαρμακου για την αγωγη της εξαρτησεως απο την κοκαϊνη
DK1365808T3 (da) Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
AR042051A1 (es) Tratamiento combinado contra el cancer con un compuesto anti-cancerigeno activado por glutationa s- transferasa (gst) y otro tratamiento contra el cancer
AR052830A1 (es) Regimen de cladribina para tratar esclerosis multiple
HUP0000137A2 (hu) Szabályozott hatóanyag-felszabadulású analgetikumot tartalmazó gyógyszerkészítmény
AR032642A1 (es) Composiciones quimioterapicas de paclitaxel en microemulsion con mayor biodisponibilidad oral.
CO5540323A2 (es) Administracion oral de hormona paratiroides y calcitonina
CO5570661A2 (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina
AR036085A1 (es) Formas de dosificacion y procedimiento para su fabricacion
UY26422A1 (es) Método para administrar un inhibidor de fosfodiesterasa 4
PA8523101A1 (es) Composicion de eletriptan en forma de particulas
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
AR036877A1 (es) Formulacion farmaceutica

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160615